Gansu Lanyao Pharmaceutical Co Ltd.

Primary objective: Using the imported afatinib maleate tablets (GIOTRIF®, 40 mg) originally developed by Boehringer Ingelheim International GmbH as the reference preparation and the afatinib maleate tablets (40 mg) produced by Gansu Lanyao Pharmaceutical Co., Ltd. as the test preparation, the bioequivalence of the two preparations in the fasting state was evaluated through a single-center, randomized, open, two-period, double-crossover clinical trial. Secondary objective: To evaluate the safety of the test preparation and the reference preparation in healthy Chinese subjects.